CNTB Connect Biopharma Holdings: רווח למניה בשנים עשר החודשים האחרונים

Connect Biopharma (CNTB) is expanding its collaboration with global clinics, advancing molecules toward the final stages of trials. The company's EPS TTM trend captures this progress, where the -1.20 mark characterizes this parameter. The financial foundation is built on the sale of dermatitis treatments in the US and China, licensing fees from partners, and the development of skin inflammation therapies.

To minimize long-term risks, it is essential for investors to evaluate the real profitability of a business. This indicator calculates the net income distributed per share over a rolling year, eliminating temporary gaps between reports. Analyzing the trailing twelve months (TTM) net income per share for Connect Biopharma (CNTB), the current value is -1.20. This trend reflects the financial stability of Connect Biopharma while developing costly therapeutic drugs in the US and China.